JUN 1 4 2004 55

PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE guired to respond to a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 19

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number 10/734,917

Filing Date 12/12/2003

First Named Inventor David J. Dooley

Art Unit 1621

Examiner Name Unknown

Attorney Docket Number PC25870A

Examiner	Cito	Danis and March	Dublication C	DOCUMENTS			
Initials*	Cite No.1	Document Number Number-Kind Code ² (f known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
y		US- 4,024,175	05-17-1977	G. Satzinger, et al.			
		^{US-} 4,087,544	05-02-1978	G. Satzinger, et al.			
42		US- 6,306,910	10-23-2001	L. Magnus, et al.			
		US-					
		US-					
		US-					
		US-					
		US-					
		US-	<u> </u>				
		US-					
		US-					
		US-					
		U\$-					
		US-					
		US-					
		U\$-					
		US-			-		
		U\$-	- 				
		US-					

		FORE	IGN PATENT DOCL	MENTS		
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	
	<u> </u>	Country Code ³ Number ⁴ Kind Code ⁵ (# known)	MM-DD-YYYY	The state of the s		
QC	EP	0641330 B1	10-17-2001	R. B. Silverman, et al.		
	WO	98/17627 A1	04-30-1998	J. S. Bryans, et al.		
	WO	99/21824 A1	05-06-1999	J. S. Bryans, et al.		
		00/76958 A2	12-21-2000	T. R. Belliotti, et al.		
	wo	01/28978 A1		J. S. Bryans, et al.		Г
W	wo	01/90052 A1		J. S. Bryans, et al.		T

<u> </u>			
Examiner		Date	,
Signature			10-1.71
angina mire	(L) \	Considered	[(V) X ()
	<u> </u>	1	
45-144-14-14	1 10 1 10 10 10 10 10 10 10 10 10 10 10		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation in to in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

Transation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Please type a plus sign (+) inside this box ->	\Box
- Share him order / mores and some	1 T I

Sheet

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				Complete if Known			
	0011.7101		1001 00115-	Application Number	10/734,917		
INF	UKMATIO	N D	ISCLOSURE	Filing Date	December 12, 2003		
STA	TEMENT	BY	APPLICANT	First Named Inventor	David J. Dooley		
				Group Art Unit	1621		
	(use as many s	heets	s as necessary)	Examiner Name	Unknown		
heet	2	of	2	Attorney Docket Number	PC25870A		

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, pege(s), volume-issue number(s), publisher, city and/or country where published.	Ls
\propto		M. V. AMERINGEN et al., "Drugs in development for social anxiety disorder:more to social anxiety than meets the SSRI" Expert Opinion on Investigational Drugs, Ashley Pub. Ltd., London, GB 2000:2215-2231; Vol.9, No. 10	
		A. BARKHUIZEN, "Rational and targeted pharmacologic treatment of fibromyalgia" Rheum Dis Clin N Am 2002;28:261-290	
		R. M. BENNETT, "The rational management of fibromyalgia patients" Rheum Dis Clin N Am 2002; 28: 181-199	
		D. BUSKILA, "Fibromyalgia, chronic fatigue syndrome and myofacial pain syndrome" Current opinions in Rheumatology 2001;13:117-127	
		B. L. EHRENBERG, et al., "Open-Label Trial of Gabapentin for Periodic Limb Movement Disorder of Sleep", 1997, pp A278-A279, Vol. 48	
		E. K. GUYMER, et al., "An approach to managing fibromyalgia" Medicine Today 2002:58-59; Vol. 3, No. 12	
		L. J. LEVENTHAL, "Management of fibromyalgia" Ann Intern Med 1999;131:850-8	
		L. T. MELTZER, et al., "Pregabalin enhances non-rapid eye movement sleep and eeg slow-wave activity in rats" Society for neuro. abstracts 2001:2245 Vol. 27, No. 2	
		I. SELAK, "Pregabalin (Pfizer)" Current opinion in investigational drugs, current drugs, Lond, GB 2001:828-834; Vol. 2, No. 6	
		F. WOLFE, et al., "The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: Report of the Multicenter Criteria Committee" Arthritis Rheum 1990; 33:160-72	
\$		M. B. YUNUS. "A comprehensive medical evaluation of patients with fibromyalgia syndrome" Rheum Dis N Am 2002; 28:201-217	

Examiner R As 1	Date	164
Signature (()	Considered	INCA
	00113146164	(4)

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.





^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Please	type	a plus	sign (+) inside	this	box	→	+	
--------	------	--------	---------	----------	------	-----	----------	---	--

PTO/SB/08B (08-00)

Please type a plus sign (+) inside this box

+ Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO SUPPLEMENTAL

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known **Application Number** 10/734,917 December 12, 2003 Filing Date David J. Dooley First Named Inventor 1621 Group Art Unit Unknown **Examiner Name** Attorney Docket Number PC25870A

(use as many sheets as necessary) Sheet of

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Examiner Cite Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), Initials' No. publisher, city and/or country where published. D. Garcia-Borreguero et al., "Treatment of restless legs syndrome with gabapentin--A double-blind, cross-over study" Neurology 2002;59:1573-1579 S

Examiner

Signature

Date

Considered

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.